marijuana stocks

American Cannabis Company Announces Two Client Product Orders Totaling $285,000

American Cannabis Company, Inc. (AMMJ) (the “Company”), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced its receipt of two client orders for cultivation equipment totaling $285,000. The Company expects to begin fulfilling this order in September 2015.

“It is exciting to see our client’s progress and the dedicated efforts of our talented team resulting in the advancement of next generation cannabis cultivation center build-outs. With the development of in state product testing programs, facility design is one of the most critical components to sustainable success over the long-term.” Corey Hollister, CEO, American Cannabis Consulting

About American Cannabis Company, Inc.:

American Cannabis Company, Inc. offers end-to-end solutions to existing and aspiring participants in the cannabis industry. We utilize our industry expertise to provide business planning and market assessment services, assist state licensing procurement, create business infrastructure and operational best practices. Through our two vertically integrated businesses, American Cannabis Consulting and American Cultivator Company, a group purchasing organization, we support our clients from concept to creation to commercialization to on-going operations.

For more information, please visit:

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please


Steven Lico
Marketing Coordinator
(303) 974-4770

SOURCE: American Cannabis Company, Inc.

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 |
Leave a Reply

Your email address will not be published.

You May Also Like

$AMMJ Income Statement

American Cannabis Company, Inc. (AMMJ)   Income Statement Get Income Statement for:…

$MDBX to Consult on Second Marijuana Dispensary In the State of Washington

Medbox to Consult on Second Marijuana Dispensary In the State of Washington…

Canopy Growth Corporation (CGC) Signs U.S. Distribution Agreement with Southern Glazer’s Wine & Spirits

Canopy Growth Signs U.S. Distribution Agreement with Southern Glazer’s Wine & Spirits…

$PMCB International Diabetes Consortium

PharmaCyte Biotech’s International Diabetes Consortium Sets Path Forward to Develop Novel Treatment…